

UC Irvine

UC Irvine Previously Published Works

Title

Decipher correlation patterns post prostatectomy: initial experience from 2 342 prospective patients

Permalink

<https://escholarship.org/uc/item/1pm916t6>

Journal

Prostate Cancer and Prostatic Diseases, 19(4)

ISSN

1365-7852

Authors

Den, RB
Santiago-Jimenez, M
Alter, J
[et al.](#)

Publication Date

2016-12-01

DOI

10.1038/pcan.2016.38

Peer reviewed

ORIGINAL ARTICLE

Decipher correlation patterns post prostatectomy: initial experience from 2342 prospective patients

RB Den¹, M Santiago-Jimenez², J Alter², M Schliekelman², JR Wagner³, JF Renzulli II⁴, DI Lee⁵, CG Brito⁶, K Monahan⁷, B Gburek⁶, N Kella⁸, G Vallabhan⁹, F Abdollah¹⁰, EJ Trabulsi¹¹, CD Lallas¹¹, LG Gomella¹¹, TL Woodlief¹², Z Haddad², LLC Lam², S Deheshi², Q Wang², V Choerung², M du Plessis², J Jordan², B Parks², H Shin², C Buerki², K Yousefi², E Davicioni², VR Patel¹² and NL Shah^{2,13}

BACKGROUND: Currently, there are multiple commercially available RNA-based biomarkers that are Medicare approved and suggested for use by the National Comprehensive Cancer Network guidelines. There is uncertainty as to which patients benefit from genomic testing and for whom these tests should be ordered. Here, we examined the correlation patterns of Decipher assay to understand the relationship between the Decipher and patient tumor characteristics.

METHODS: De-identified Decipher test results (including Decipher risk scores and clinicopathologic data) from 2342 consecutive radical prostatectomy (RP) patients tested between January and September 2015 were analyzed. For clinical testing, tumor specimen from the highest Gleason grade was sampled using a 1.5 mm tissue punch. Decipher scores were calculated based on a previously locked model. Correlations between Decipher score and clinicopathologic variables were computed using Spearman's rank correlation. Mixed-effect linear models were used to study the association of practice type and Decipher score. The significance level was 0.05 for all tests.

RESULTS: Decipher score had a positive correlation with pathologic Gleason score (PGS; $r=0.37$, 95% confidence interval (CI) 0.34–0.41), pathologic T-stage ($r=0.31$, 95% CI 0.28–0.35), CAPRA-S ($r=0.32$, 95% CI 0.28–0.37) and patient age ($r=0.09$, 95% CI 0.05–0.13). Decipher reclassified 52%, 76% and 40% of patients in CAPRA-S low-, intermediate- and high-risk groups, respectively. We detected a 28% incidence of high-risk disease through the Decipher score in pT2 patients and 7% low risk in pT3b/pT4, PGS 8–10 patients. There was no significant difference in the Decipher score between patients from community centers and those from academic centers ($P=0.82$).

CONCLUSIONS: Although Decipher correlated with baseline tumor characteristics for over 2000 patients, there was significant reclassification of tumor aggressiveness as compared to clinical parameters alone. Utilization of the Decipher genomic classifier can have major implications in assessment of postoperative risk that may impact physician-patient decision making and ultimately patient management.

Prostate Cancer and Prostatic Diseases (2016) **19**, 374–379; doi:10.1038/pcan.2016.38; published online 30 August 2016

INTRODUCTION

The management of men with prostate cancer is continuously evolving. Significant controversy exists with regard to the appropriate utilization and timing of adjuvant vs salvage therapies. Novel RNA-based genomic signatures are aiding patients and physicians in selection of primary therapy,^{1,2} as well as with postoperative treatment options.^{3–11} While these assays provide important prognostic information, only the Decipher prostate cancer classifier has been shown to be predictive¹² and consideration for its use in the post-radical prostatectomy (RP) setting has been suggested by the National Comprehensive Cancer Network guidelines.¹³ Decipher has also been validated for prediction of metastasis among patients who experience biochemical recurrence and in the salvage radiotherapy setting post RP.^{10,14} The Decipher post-op test is marketed to patients with adverse clinical or pathologic findings (e.g., pathologic stage T2 with positive margins, any pT3 disease or

biochemical recurrence). Currently, there is uncertainty as to which patients benefit from genomic testing and thus for whom these tests should be ordered. Hence, we examined the commercial correlation patterns of the Decipher assay to understand the relationship between the genomic classifier score and patients' tumor characteristics and to gain insight into the potential impact on altering postoperative therapy decisions for this patient population.

MATERIALS AND METHODS

Study cohort

We identified 2504 consecutive RP patients from academic and community health centers for whom the Decipher test was ordered between 1 January and 1 September 2015. The tests were ordered by physicians at the originating institutions for patient management in the post-prostatectomy setting. Only patient samples that passed microarray quality control (QC) metrics were included in this study ($n=2342$).

¹Department of Radiation Oncology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA; ²GenomeDx Biosciences Inc., Vancouver, BC, Canada;

³Urologic Oncology and Minimally Invasive Surgery, Hartford Healthcare Medical Group, Hartford, CT, USA; ⁴Section of Minimally Invasive Urology, The Warren Alpert Medical School of Brown University, Providence, RI, USA; ⁵Division of Urology, Penn Presbyterian Medical Center, Philadelphia, PA, USA; ⁶Arizona Urology Specialists, Scottsdale, AZ, USA;

⁷Penn Urology, Philadelphia, PA, USA; ⁸The Urology and Prostate Institute, San Antonio, TX, USA; ⁹Lubbock Urology, Lubbock, TX, USA; ¹⁰Vattikuti Urology Institute, Henry Ford Hospital, Detroit, MI, USA; ¹¹Department of Urology, Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, PA, USA; ¹²Global Robotics Institute, Celebration, FL, USA and ¹³Piedmont Health Care, Atlanta, GA, USA. Correspondence: Dr RB Den, Department of Radiation Oncology, Sidney Kimmel Medical College of Thomas Jefferson University, 111 South 11th Street, Room G-301, Bodine Center, Philadelphia, PA 19107, USA.

E-mail: Robert.Den@jeffersonhospital.org

Received 3 March 2016; revised 19 April 2016; accepted 17 May 2016; published online 30 August 2016

Microarray QC was verified using Affymetrix power tools¹⁵ and was performed by running the specimens through an internal QC pipeline that flags specimens that fail microarray QC metrics as described previously.^{4,5} The proportion of patient samples that failed microarray QC metrics was 5.9% (162 samples), of which 64.8% had insufficient signal (low percent present of probes on the microarray) and the rest did not meet the other required QC metrics for hybridization and overall signal quality. The microarray QC failed samples were distributed across 45/303 ordering centers (1–5 failed samples per center) and the average monthly QC failure rate was 5.3%. None of the patients in the current study were part of previously reported validation studies of Decipher. All patient-related data were de-identified and study researchers were blinded to patient identities and did not have access to personally identifiable health information.

Specimen selection and processing

Dedicated genitourinary pathologists from originating institutions graded all tumors using the International Society of Urological Pathology 2005 Gleason grading criteria.¹⁶ For lab processing, only the formalin-fixed paraffin-embedded block submitted for Decipher testing was reviewed. The submitted formalin-fixed paraffin-embedded block for molecular analysis contained the index prostate cancer lesion with the highest stage and tumor grade, and was sampled using a 1.5 mm tissue punch tool provided in the specimen kit.

Calculation of CAPRA-S and Decipher

CAPRA-S score was derived from a Cox regression equation using six variables: preoperative PSA, pathologic Gleason score (PGS), surgical margin status, extra-prostatic extension, seminal vesicle invasion and lymph node invasion.¹⁷

The expression values for the 22 pre-specified biomarkers that constitute Decipher were extracted from the normalized data matrix and entered into the locked random forest algorithm with tuning and weighting parameters defined as reported previously.⁵ The Decipher read-out is a continuous risk score between 0 and 1, with higher scores indicating a greater probability of metastasis and prostate cancer-specific mortality.⁷ Validated low- (< 0.45), intermediate- (0.45–0.60) and high-risk (> 0.60) groups of Decipher were used for categorical analyses.⁵

Statistical analyses

Descriptive statistics of variables focused on medians and interquartile ranges (IQR) or frequencies and proportions as appropriate. To compare clinico-pathologic variables across practice types, Fisher’s exact test and analysis of variance *F* test were used for categorical and continuous variables, respectively. Correlations between Decipher score and age categories, PGS, pathologic stage and CAPRA-S were computed using Spearman’s rank correlation. Linear regression analysis was used to compare Decipher scores in patients with and without tertiary Gleason pattern. A mixed-effect linear model was fitted to study the association between practice type and Decipher score. In this analysis, institution was modelled as a random effect to adjust for its possible bias on Decipher variations. All statistical tests were two-sided and had a significance level of 0.05. Analyses were performed in R v3.1 (R Foundation, Vienna, Austria).

RESULTS

Patient characteristics and utilization patterns in the ordering centers

Demographic, clinical and pathological characteristics of the study cohort are provided in Table 1. Breakdown of study cohort by practice type is provided in Supplementary Table 1. Overall, 10.6% of patients came from academic practice centers compared to 89.3% from community centers. Median patient age at RP was 66 years (IQR, 60–69). Median time between RP and ordering of Decipher was 3.6 months (IQR, 0.8–14.8). Fifty-four percent of patients had positive surgical margins and 60.6% had pT3 or higher disease; 7.9%, 38.4%, 28.8%, 10.7% and 14.0% had PGS 3+3, 3+4, 4+3, 8 and 9–10, respectively. Only 14.9% (*n*=349) of tests were performed for patients with pT2R0 disease and, of these, 21 (0.9%) had Gleason 6 disease. Decipher tests ordered by practitioners in academic centers were for higher-risk patients as

Table 1. Clinical and pathological characteristics of the study cohort

Variables	Study cohort
No. of patients	2342
<i>Practice type</i>	
Academic	249 (10.6%)
Community	2092 (89.3%)
Unknown	1 (0%)
<i>Age at RP</i>	
Median (range)	66 (40–84)
IQR (Q1, Q3)	(60–69)
<i>Time between RP and ordering of Decipher (months)</i>	
Median (range)	3.6 (0.1–102)
IQR (Q1, Q3)	(0.8–14.8)
<i>Pre-op PSA (ng⁻¹ml)</i>	
Median (range)	6.4 (0–150)
IQR (Q1, Q3)	(4.7–9.6)
< 10 ng ml ⁻¹	1265 (54.0%)
10–20 ng ml ⁻¹	277 (11.8%)
> 20 ng ml ⁻¹	110 (4.7%)
Unknown	690 (29.5%)
<i>Extra-prostatic extension, n (%)</i>	
Present	1297 (55.4%)
<i>Seminal vesicle invasion,^a n (%)</i>	
Present	504 (21.5%)
<i>Surgical margin,^a n (%)</i>	
Positive	1271 (54.3%)
<i>Lymph node invasion,^a n (%)</i>	
Positive	61 (2.6%)
<i>Pathologic Gleason score, n (%)</i>	
6	186 (7.9%)
7	
(3+4)	900 (38.4%)
(4+3)	674 (28.8%)
8	251 (10.7%)
9–10	328 (14.0%)
Unknown	3 (0.1%)
<i>Pathological stage, n (%)</i>	
T2R0	349 (14.9%)
T2R1	564 (24.1%)
T3a	903 (38.6%)
T3b	501 (21.4%)
T4	14 (0.6%)
Unknown	11 (0.5%)

Abbreviations: IQR, interquartile range; RP, radical prostatectomy.
^aUnknown seminal vesicle invasion, surgical margin and lymph node invasion status for 11, 6 and 95 patients, respectively.

judged by the greater proportion of Gleason 9–10 tumors (18.5% vs 13.5%, *P* < 0.03) and patients with lymph node invasion (6.8% vs 2.1%, *P* < 0.001), whereas in the community-based practice a higher proportion of tests were ordered for older men (median 66 vs 64 years old, *P* < 0.001) who had higher rate of positive surgical margins (55.2% vs 46.6%, *P* < 0.01) (Supplementary Table 1).

Overall, of the 303 ordering centers, 172 (56.8%), 67 (22.1%), 51 (16.8%) and 13 (4.3%) ordered 1–3, 4–9, 10–39 and 40 or more Decipher tests, respectively (Supplementary Table 2). These groups of ordering centers represent 11.5%, 16.1%, 37.2% and 35.1% of the entire study cohort, respectively.

Correlation of Decipher score with PGS, pathologic stage and CAPRA-S

Figure 1 provides the correlation of Decipher score with PGS and pathologic stage. Decipher score had a positive Spearman’s correlation of 0.37 (95% confidence interval (CI) 0.34–0.41) with




Figure 1. Correlation of Decipher score with (a) pathologic Gleason score; (b) pathologic stage.




Figure 2. Correlation of Decipher score and CAPRA-S.

PGS (Figure 1a). Similar results were observed between Decipher score and pathologic stage as patients with favorable pathology had significantly lower Decipher scores (Figure 1b; Spearman’s correlation of 0.31; 95% CI 0.28–0.35). We also assessed the association between Decipher score and CAPRA-S. This analysis showed that Decipher had a positive Spearman’s correlation of 0.32 (95% CI: 0.28–0.37) with CAPRA-S (Figure 2).

Decipher reclassifies patients assigned to risk groups by PGS, pathologic stage and CAPRA-S

Decipher classification by PGS and pathologic stage is provided in Table 2. Of the 2243 (95.8%) patients with available pathologic data, Decipher classified 35.8%, 23.1% and 41.1% as low-, intermediate- and high-risk, respectively. Decipher provided independent information and reclassified patients within PGS and pathologic stage categories (Table 2). For instance, 10% of patients with PGS 3+3 and pT2 stage were classified as high-risk, while 7% of patients with PGS 8–10 and pT3b/pT4 disease were classified as low-risk by Decipher.

Risk stratification of patients by CAPRA-S to Decipher is shown in Supplementary Figure 1. Of the 2342 patients in the study, 1586 (67.7%) had available CAPRA-S score. Of these, 19.2%, 52.0% and 28.8% were classified as low-, intermediate- and high-risk, respectively. In contrast, Decipher classified 35.8%, 22.7% and 41.5% of these patients as low-, intermediate- and high-risk, respectively. Decipher classification within CAPRA-S score categories is provided in Figure 3. Decipher reclassified 52%, 76% and 40% of patients in CAPRA-S low-, intermediate- and high-risk groups, respectively.

Association of Decipher score with tertiary 5 Gleason pattern

Among patients with PGS 3+4 and 4+3, 99 (11.0%) and 155 (23.0%) had a tertiary Gleason pattern 5, respectively. Among patients with PGS 3+4 and 4+3, those with a tertiary pattern had +0.09 (95% CI: 0.05–0.14) and +0.08 (95% CI: 0.05–0.12) higher Decipher score on average, respectively (Figure 4). The linear model with PGS and tertiary pattern as predictors and Decipher score as a response variable showed that patients with tertiary

Table 2. Decipher classification with pathologic Gleason score and pathologic stage risk groups

Decipher	Gleason score ^d														
	3+3			3+4			4+3			8-10			Total		
	Low	Int	High	Low	Int	High	Low	Int	High	Low	Int	High	Low	Int	High
pT2	74 (64%)	30 (26%)	12 (10%)	221 (56%)	85 (22%)	87 (22%)	71 (39%)	44 (24%)	68 (37%)	46 (30%)	37 (24%)	71 (46%)	412 (49%)	196 (23%)	238 (28%)
pT3a	29 (64%)	9 (20%)	7 (16%)	150 (45%)	78 (23%)	104 (31%)	91 (30%)	89 (29%)	126 (41%)	39 (22%)	38 (21%)	103 (57%)	309 (36%)	214 (25%)	340 (39%)
pT3b/pT4	6 (50%)	3 (25%)	3 (25%)	29 (24%)	30 (25%)	60 (50%)	21 (14%)	30 (20%)	97 (66%)	14 (7%)	32 (16%)	148 (76%)	70 (15%)	95 (20%)	308 (65%)
Total	109 (63%)	42 (24%)	22 (13%)	400 (47%)	193 (23%)	251 (30%)	183 (29%)	163 (26%)	291 (46%)	99 (19%)	107 (20%)	322 (61%)	791 (36%)	505 (23%)	886 (41%)

Ninety nine patients with unknown pathologic stage or pathologic Gleason score or lymph node data were excluded. ^aExcluding lymph node-positive patients.




Figure 3. Decipher stratification within low, intermediate, and high CAPRA-S risk groups.




Figure 4. Association of Decipher score with tertiary Gleason pattern 5 among patients with pathologic Gleason score 3+4 and 4+3. T refers to tertiary Gleason pattern 5.

Gleason pattern 5 had +0.09 (95% CI 0.06 – 0.12; $P < 0.001$) higher Decipher scores on average than patients without tertiary pattern after adjusting for PGS (Supplementary Table 3).

Decipher score in community vs academic practice centers

The multivariable linear mixed effect model with institution as a random effect showed no significant difference ($P = 0.82$) in Decipher scores between academic and community practice centers after adjusting for clinico-pathologic variables (Supplementary Table 4).

Association of Decipher score with age categories

Decipher score had a positive Spearman’s correlation of 0.09 (95% CI 0.05-0.13, $P < 0.001$) with patient age (Figure 5). In this analysis, 54% of patients aged < 50 were categorized as low risk while only 30% of patients who were 70 or older were categorized as low




Figure 5. Decipher stratification within age categories.

Decipher risk. However, after adjusting for PSA, PGS, surgical margin status, extra-prostatic extension, seminal vesicle invasion and lymph node invasion, the association between age at prostatectomy and Decipher score was not statistically significant.

DISCUSSION

The delivery and timing of post-operative radiation therapy is controversial within the medical community.¹⁸ While multiple randomized studies¹⁹⁻²¹ have demonstrated an improvement in biochemical recurrence with immediate (adjuvant) post-prostatectomy radiation for men with either pathologic T3 disease or positive margins, an improvement in overall survival has been shown in only one study.²² Further, 50% of patients who were randomized to observation following prostatectomy never developed further disease progression. This has led many to advocate for offering post-operative radiation therapy only in the setting of a detectable PSA (salvage) with close monitoring of PSA, most often at a PSA > 0.2 ngml⁻¹.²³

We have recently demonstrated that integration of a genomic classifier can distinguish patients who would benefit from adjuvant radiation therapy from those who can be safely treated with salvage radiation therapy.¹² There was no statistically significant difference in cumulative incidence of metastasis for men classified as low risk by Decipher regardless of whether they had received adjuvant vs salvage radiation therapy. However, there was a clinically meaningful and statistically significant decrease in cumulative incidence of metastasis with administration of adjuvant as opposed to salvage radiation therapy for men classified as Decipher high risk.

Multiple studies have established that, when provided hypothetical cases, physicians will alter management decisions based on genomic data.²⁴⁻²⁶ Further, decision curve analysis demonstrates that, when compared to scenarios where no prediction model would be used for a post-operative radiation treatment decision (that is, ‘treat all’ or ‘treat none’), genomic classifier-based models had a higher net benefit than clinical models across a wide range of decision threshold probabilities.²⁷ These studies emphasize the importance of genomic markers in making patient management decisions. Given the potential for toxicity with post-operative

therapy as radiation, hormonal or chemotherapy balanced against the potential for cure, more information will assist in patient decision-making. Forthcoming, prospective studies are necessary and vital to ensure that these findings are valid as bias can be reduced.

Our current study demonstrates several salient features. First, the majority of patients were referred from community practices, demonstrating the adoption of the Decipher genomic classifier in current practice within the US.²⁸ Second, we believe this is the first demonstration in prospective usage that the genomic classifier correlates with both pathologic stage and PGS and it provides unique patient-specific information. Third, the high percentages of positive surgical margins and pT3 or higher disease in this study are reflective of the marketed indications of the Decipher test (that is, the presence of adverse pathologic or clinical findings). Fourth, only a small fraction of tests (0.9%) were ordered in node negative patients with pT2R0 disease and pathologic Gleason 6. For patients in whom post-operative radiation is not currently indicated (pathologic T2 and margin negative), 25% of men had high-risk disease as determined by the genomic classifier. Conversely, in patients typically considered for adjuvant radiation therapy (pathologic T3 or greater and Gleason score 8–10), 18% of men were classified as having low-risk disease. Finally, assuming that all men with pT3 or positive margins received adjuvant radiation therapy, utilization of the genomic classifier would reduce usage in the low-risk population by approximately 36%.

Our study is not without limitations. First, we do not have long-term follow-up on the patients analyzed to determine the actuarial metastatic incidence. Furthermore, while robust, the genomic classifier provides an estimate for incidence of metastatic disease for a given patient over a 5- and 10-year period, which is not absolute. Third, the predicted incidence of metastasis may decrease with more aggressive therapy being offered earlier to patients at higher risk of disease;²⁹ however, no post-operative treatment information is currently available for these patients. Fourth, while the assay informs clinical decision making, selection of further therapy, by either the physician or the patient, was not captured in this initial experience and will be reported in subsequent analyses.

CONCLUSIONS

While Decipher correlated with baseline tumor characteristics for over 2 000 patients whose tumor specimens underwent genomic testing, there was significant reclassification of tumor aggressiveness as compared to risk assessment based on clinical parameters alone. Patients and providers can determine their willingness to accept a given threshold risk of metastasis and determine whether genomic testing would be beneficial. Given the wide distribution of risk classification and potential of the genomic classifier score to reclassify patients and thereby alter management between observation, adjuvant or salvage radiation therapy following prostatectomy, genomic testing could be a helpful tool within the post-operative setting.

CONFLICT OF INTEREST

GenomeDx Biosciences had a role in sponsoring the data and material in this study. M Santiago-Jimenez, J Alter, M Schliekelman, Z Haddad, LLC Lam, S Dehesi, Q Wang, V Choerung, M du Plessis, J Jordan, B Parks, H Shin, C Buerki, K Yousefi, E Davicioni and NL Shah are employees of GenomeDx Biosciences. F Abdollah is a consultant for GenomeDx Biosciences. RB Den reports an unrestricted research grant from GenomeDx Biosciences. VR Patel is a consultant for GenomeDx Biosciences. The remaining authors declare no conflict of interest.

ACKNOWLEDGEMENTS

Preparation and submission of the manuscript: Kaye Ong.

REFERENCES

- 1 Cuzick J, Swanson GP, Fisher G, Brothman AR, Berney DM, Reid JE *et al*. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. *Lancet Oncol* 2011; **12**: 245–255.
- 2 Klein EA, Cooperberg MR, Magi-Galluzzi C, Simko JP, Falzarano SM, Maddala T *et al*. A 17-gene assay to predict prostate cancer aggressiveness in the context of gleason grade heterogeneity, tumor multifocality, and biopsy undersampling. *Eur Urol* 2014; **66**: 550–560.
- 3 Cooperberg MR, Simko JP, Cowan JE, Reid JE, Djalilvand A, Bhatnagar S *et al*. Validation of a cell-cycle progression gene panel to improve risk stratification in a contemporary prostatectomy cohort. *J Clin Oncol* 2013; **31**: 1428–1434.
- 4 Erho N, Crisan A, Vergara IA, Mitra AP, Ghadessi M, Buerki C *et al*. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. *PLoS One* 2013; **8**: e66855.
- 5 Jeffrey Karnes R, Bergstralh EJ, Davicioni E, Ghadessi M, Buerki C, Mitra AP *et al*. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk Patient population. *J Urol* 2013; **190**: 2047–2053.
- 6 Klein EA, Yousefi K, Haddad Z, Choerung V, Buerki C, Stephenson AJ *et al*. A genomic classifier improves prediction of metastatic disease within 5 years after surgery in node-negative high-risk prostate cancer patients managed by radical prostatectomy without adjuvant therapy. *Eur Urol* 2015; **67**: 778–786.
- 7 Cooperberg MR, Davicioni E, Crisan A, Jenkins RB, Ghadessi M, Karnes RJ. Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. *Eur Urol* 2015; **67**: 326–333.
- 8 Ross AE, Johnson MH, Yousefi K, Davicioni E, Netto GJ, Marchionni L *et al*. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk Men. *Eur Urol* 2015; **69**: 157–165.
- 9 Glass AG, Leo MC, Haddad Z, Yousefi K, du Plessis M, Chen C *et al*. Validation of a genomic classifier for predicting post-prostatectomy recurrence in a community-based healthcare setting. *J Urol* 2015; **195**: 1748–1753.
- 10 Freedland SJ, Choerung V, Howard L, De Hoedt A, du Plessis M, Yousefi K *et al*. Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy. *Eur Urol* 2016 (e-pub ahead of print 21 Jan 2016; doi:10.1016/j.eururo.2016.01.008).
- 11 Klein EA, Haddad Z, Yousefi K, Lam LL, Wang Q, Choerung V *et al*. Decipher genomic classifier measured on prostate biopsy predicts metastasis risk. *Urology* 2016; **90**: 148–152.

- 12 Den RB, Yousefi K, Trabulsi EJ, Abdollah F, Choerung V, Feng FY *et al*. Genomic classifier identifies men with adverse pathology after radical prostatectomy who benefit from adjuvant radiation therapy. *J Clin Oncol* 2015; **33**: 944–951.
- 13 Mohler JL, Armstrong AJ, Bahnson RR, D'Amico AV, Davis BJ, Eastham JA *et al*. Prostate Cancer, Version 1. 2016. *J Natl Compr Canc Netw* 2016; **14**: 19–30.
- 14 Ross AE, Feng FY, Ghadessi M, Erho N, Crisan A, Buerki C *et al*. A genomic classifier predicting metastatic disease progression in men with biochemical recurrence after prostatectomy. *Prostate Cancer Prostatic Dis* 2014; **17**: 64–69.
- 15 Lockstone HE. Exon array data analysis using Affymetrix power tools and R statistical software. *Brief Bioinform* 2011; **12**: 634–644.
- 16 Epstein JI, Allsbrook WC Jr, Amin MB, Egevad LL A, Committee the IG. The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma. *Am J Surg Pathol* 2005; **29**: 1228–1242.
- 17 Cooperberg MR, Hilton JF, Carroll PR. The CAPRA-S score: A straightforward tool for improved prediction of outcomes after radical prostatectomy. *Cancer* 2011; **117**: 5039–5046.
- 18 Kim SP, Tilburt JC, Karnes RJ, Ziegenfuss JY, Han LC, Shah ND *et al*. Variation in treatment recommendations of adjuvant radiation therapy for high-risk prostate cancer by physician specialty. *Urology* 2013; **82**: 807–812.
- 19 Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D *et al*. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. *Jama* 2006; **296**: 2329–2335.
- 20 Bolla M, Van Poppel H, Collette L, Van Cangh P, Vekemans K, Da Pozzo L *et al*. Postoperative radiotherapy after radical prostatectomy: A randomised controlled trial (EORTC trial 22911). *Lancet* 2005; **366**: 572–578.
- 21 Wiegel T, Bottke D, Steiner U, Siegmann A, Golz R, Störkel S *et al*. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. *J Clin Oncol* 2009; **27**: 2924–2930.
- 22 Thompson IM, Tangen CM, Paradelo J, Lucia MS, Miller G, Troyer D *et al*. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. *J Urol* 2009; **181**: 956–962.
- 23 Sineshaw HM, Gray PJ, Efstathiou J a, Jemal A. Declining use of radiotherapy for adverse features after radical prostatectomy: results from the national cancer data base. *Eur Urol* 2015; **68**: 768–774.
- 24 Nguyen PL, Shin H, Yousefi K, Thompson DJS, Hornberger J, Hyatt AS *et al*. Impact of a genomic classifier of metastatic risk on postprostatectomy treatment recommendations by radiation oncologists and urologists. *Urology* 2015; **86**: 35–40.
- 25 Badani KK, Thompson DJ, Brown G, Holmes D, Kella N, Albala D *et al*. Effect of a genomic classifier test on clinical practice decisions for patients with high-risk prostate cancer after surgery. *BJU Int* 2015; **115**: 429.
- 26 Michalopoulos SN, Kella N, Payne R, Yohannes P, Singh A, Hettinger C *et al*. Influence of a genomic classifier on postoperative treatment decisions in high-risk prostate cancer patients: Results from the PRO-ACT study. *Curr Med Res Opin* 2014; **30**: 1–10.
- 27 Den RB, Feng FY, Showalter TN, Mishra M.V, Trabulsi EJ, Lallas CD *et al*. Genomic prostate cancer classifier predicts biochemical failure and metastases in patients after postoperative radiation therapy. *Int J Radiat Oncol Biol Phys* 2014; **89**: 1038–1046.
- 28 Kirkwood BMK, Kosty MP, Bajorin DF, Bruinooge SS, Goldstein MA. Tracking the Workforce: The American Society of Clinical Oncology Workforce Information System Conclusion. *J Oncol Pract*: 2013; **9**: 3–8.
- 29 Vale CL, Burdett S, Ryzdzewska LHM, Albiges L, Clarke NW, Fisher D *et al*. Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. *Lancet Oncol* 2015; **17**: 243–256.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2016

Supplementary Information accompanies the paper on the Prostate Cancer and Prostatic Diseases website (<http://www.nature.com/pcan>)